Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 ...

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic and oncology diseases, today announced continued ...
Labroots

CNS-3D Brain Organoids Predict Clinical Seizure Liability

Central nervous system (CNS) toxicity accounts for 25% of safety failures across drug discovery and development, yet it is rarely detected during standard GLP toxicology studies 1. Seizure risk ...
Nasdaq

Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

NEW HAVEN, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, ...
National Academies of Sciences%2c Engineering%2c and Medicine

Glutamate-related Biomarkers in Drug Development for Disorders of the Nervous System – A Workshop

The Forum on Neuroscience and Nervous System Disorders hosted a public workshop on June 21-22, 2010, bringing together key stakeholders, to present promising current and emerging technologies with ...
Business Wire

Kesmalea Therapeutics Appoints Robert Johnson as CEO To Lead Development of New Class of Oral, CNS Penetrant Protein Degraders

LONDON--(BUSINESS WIRE)--Kesmalea Therapeutics, a biopharmaceutical company developing a pipeline of novel therapeutics founded on the ability to transform large protein degraders into small molecules ...
iaea.org

Central Nervous System Radiotracer Development: Bench to Bedside

This publication provides an overview of central nervous system (CNS) radiotracer development, discussing different aspects and stages of development. Non-invasive neuroimaging with radiotracers can ...